EVALUATION OF THE ACTION OF STATINS IN THERAPEUTIC MANAGEMENT OF DIABETIC DYSLIPIDEMIA, CASES OF TYPE 2 DIABETES IN LUBUMBASHI.
Keywords:Statins, Type 2 diabetes, Lubumbashi
Type 2 diabetes is preceded by a long asymptomatic phase that is often overlooked, but in which the body undergoes many changes. Diabetics have a significantly increased risk of cardiovascular diseases such as angina, heart attack, stroke or peripheral vascular disease. These complications of diabetes affecting large arteries are the particular consequences of dyslipidemia.
The objective of this study was to evaluate the effectiveness of statin group of drugs used in the drug management of dyslipidemia of type 2 diabetes in the city of Lubumbashi in the Democratic Republic of Congo.
This is a cross-sectional study conducted from June to December 2014 in Lubumbashi (DR Congo).
40 patients with type 2 confused sex with 20 drugs in the statin family, fibrates under 10 and 10 in the statin-fibrate combination were in this descriptive study. Alongside the classical laboratory tests, analysis of lipid parameters were carried out: HDL cholesterol, LDL cholesterol, total cholesterol and triglyceride.
Different levels of serum lipids were analyzed recorded based on lipid-lowering therapy. Type 2 diabetes, obese of the first class, who were treated with combination statin + fibrate, presented at least one month after treatment a normal lipid levels in all respects.
Statins are potent molecules able to stabilize lipids. However these drugs are sometimes ineffective in the treatment of dyslipidemia in type 2 diabetes when used as monotherapy. Hence the need to add to them other molecules to enhance their lipid-lowering effect through a synergy of action.
André JS. Traitement médicamenteux, les statines dans la prise en charge des dyslipidémies. La revue du praticien. 2011 oct ; 61(7) :1120-1126.
Fruchant JC., Sacks F., Hermans MP., et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Diab Vasc Res. 2008; 5(3):319-35.
Keech A., Simes RJ., Barter P. et al. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005; 366 (15): 1849 – 61.
Accord study group, Ginsberg HN., Bam MB., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362(11):1563-74.
Brucket E., Labreuche J., Amarenco P. Meta-Analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 2010; 210 (63):353-61.
Verges B. Fenofibrate therapy and cardiovascular protection in diabetes: recommandations after FIELD. Curr Opin Lipidol. 2006; 17 (4):653-658.
Rabaeus M. Cholesterol, sport et statines. Sportmedizin und sporttraumatologie. 2012; 60(4):150-152.
CTT (Cholesterol Treatment Trialists) collaborators : The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease : meta-analysis of individual data from 27 randomised trials. Lancet. 2012; 380(55):581-590.
Moulin PH. statines et prevention cardiovasculaire : utilisation et prospective. Néphrologie. 2000; 21 (7): 379 – 38.
Wood D., DeBacker G., Faergeman O., et al. Prevention of coronary heart disease in clinical practice: Recommandations of the second joint task force of European and other societies on coronary prevention. Atherosclerosis. 1998; 140(21):199-270.
Austin MA., Hokanson JE., Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998 ; 81 (Suppl. 4A) : 7B-12B.
Genest JJJ, Martin-Munley SS, Mc Namara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992 ; 85(9): 2025-33.
Lewis GF, Steiner G. Acute effects of insulin in the control of VLDL production in humans. Diab Care 1996 ; 19(5): 390-5.
James RW, Pometta D. The distribution profiles of very low density and low density lipoproteins in poorly-controlled male, type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1991 ; 34(7): 246-52.
JAMES RW. Particularités de la dyslipidémie du diabète. Revue Médicale Suisse. 2002; 617(21):70 – 72.
Ballmer PE. Tous les diabétiques devraient-ils prendre des statines et/ou des fibrates ? Forum Med Suisse. 2003, 6(3):130 – 133.
How to Cite
Copyright (c) 2021 International Education and Research Journal (IERJ)
This work is licensed under a Creative Commons Attribution 4.0 International License.